%PDF-1.4
%
31 0 obj
<>
endobj
28 0 obj
<>
endobj
85 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-10-06T19:49:25Z
2024-03-28T13:41:57-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T13:41:57-07:00
application/pdf
Heather
2002-964.nov
uuid:bb4c3f23-1dd1-11b2-0a00-010927bd7200
uuid:bb4c3f26-1dd1-11b2-0a00-880000000000
endstream
endobj
17 0 obj
<>
endobj
18 0 obj
<>
endobj
32 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 7 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 9 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 11 0 R/Type/Page>>
endobj
95 0 obj
[99 0 R]
endobj
96 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
0.0049 Tc 0.192 Tw 10 0 0 10 54 713.0005 Tm
(yohimbine suggests a dominant )Tj
/T1_1 1 Tf
0 Tc 0 Tw 13.8048 0 Td
(\002)Tj
/T1_0 1 Tf
0.0049 Tc 0.19189 Tw 0.6359 0 Td
[(-2 adrener)17.7 (gic ef)17.7 (fect as)]TJ
0.02499 Tw -14.4406 -1.2 Td
(postulated by Flavahan, )Tj
/T1_2 1 Tf
9.9703 0 Td
(et al)Tj
/T1_0 1 Tf
0 Tw 6.5 0 0 6.5 171.6983 704.3005 Tm
(13)Tj
0 Tc 10 0 0 10 178.2632 701.0005 Tm
(.)Tj
-0.00011 Tc 0.0437 Tw -11.2263 -1.2 Td
[(W)79.9 (e have described a patient with CREST)-276.1 (syndrome and)]TJ
0.01939 Tw -1.2 -1.2 Td
[(erectile dysfunction who noted worsening RP)-232.6 (when he took)]TJ
0.1537 Tw 0 -1.2 TD
(yohimbine. He may be a slow metabolizer of yohimbine,)Tj
0.08569 Tw T*
(resulting in increased catecholamine release and decreased)Tj
0.33 Tw T*
(clearance, thereby stimulating )Tj
/T1_1 1 Tf
0 Tc 0 Tw (\002)Tj
/T1_0 1 Tf
-0.00011 Tc 0.3299 Tw [0.1 (-2 adrener)17.7 (gic receptors,)]TJ
0.0582 Tw 0.0001 -1.2 Td
[(causing worsening of his symptoms. )17.7 (This is the first report)]TJ
0.06441 Tw T*
[(of aggravation of RP)-277.6 (with yohimbine, and improvement of)]TJ
0.1684 Tw T*
[(RP)-381.6 (and ED with a combination of felodipine and topical)]TJ
0 Tw T*
(nitroglycerin.)Tj
/T1_3 1 Tf
0 -2.4 TD
(REFERENCES)Tj
/T1_0 1 Tf
0.02499 Tw 8 0 0 8 61 559.0005 Tm
[(1.)-875.1 (Ernst E, Pittler MH. )36.8 (Y)99.8 (ohimbine for erectile dysfunction: a )]TJ
1.675 -1.25 Td
(systematic review and meta-analysis of randomized clinical trials. )Tj
0 -1.25 TD
(J Urol 1998;159:433-6.)Tj
-1.675 -1.25 Td
[(2.)-875.1 (Goldber)17.7 (g MR, Robertson D. )36.8 (Y)99.8 (ohimbine: a pharmacological probe)]TJ
1.675 -1.25 Td
[(for study of the alpha-2 adrenoreceptor)54.8 (. Pharmacol Rev)]TJ
0 Tc 0 Tw T*
(1983;35:143-80.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(3.)-875.1 (Baum N. )17.7 (T)35 (reatment of impotence. 1. Nonsur)17.7 (gical methods.)]TJ
1.675 -1.25 Td
(Postgrad Med 1987;81:133-6.)Tj
-1.675 -1.25 Td
[(4.)-875.1 (Raynaud M. De la gangrene symetrique des extremites. Paris:)]TJ
1.675 -1.25 Td
(Universite de Paris; 1862.)Tj
31.325 30.6911 Td
[(5.)-875.1 (T)69.9 (owheed )17.7 (T)74 (, Dewar C. )54.8 (A)-220.1 (practical approach to Raynaud\325)54.8 (s syndrome.)]TJ
1.675 -1.25 Td
[(Medicine N )54.8 (Am 1996;19:56-60.)]TJ
-1.675 -1.25 Td
[(6.)-875.1 (Sandler B, )54.8 (Aronson P)110.7 (.)-0.1 ( )36.8 (Y)99.8 (ohimbine-induced cutaneous drug eruption,)]TJ
1.675 -1.25 Td
(progressive renal failure, and lupus-like syndrome. Urology)Tj
0 Tc 0 Tw T*
(1993;41:343-5.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(7.)-875.1 (Corbin JD, Francis SH, )17.7 (W)79.9 (ebb DJ. Phosphodiesterase type 5 as a)]TJ
1.675 -1.25 Td
[(pharmacologic tar)17.7 (get in erectile dysfunction. Urology )]TJ
0 Tw T*
[(2002;60:4-1)36.8 (1.)]TJ
0.02499 Tw -1.675 -1.25 Td
[(8.)-875.1 (Kloner RA, Zusman RM. Cardiovascular ef)17.7 (fects of sildenafil citrate)]TJ
1.675 -1.25 Td
[(and recommendations for its use. )54.8 (Am J Cardiol 1999;84:1)36.8 (1N-17N.)]TJ
-1.675 -1.25 Td
[(9.)-875.1 (Freedman RR, Baer RP)110.7 (, Mayes MD. Blockade of vasospastic)]TJ
1.675 -1.25 Td
[(attacks by alpha-2 adrener)17.7 (gic but not alpha-1 adrener)17.7 (gic antagonists)]TJ
T*
[(in idiopathic Raynaud\325)54.8 (s disease. Circulation 1995;92:1448-51.)]TJ
-2.175 -1.25 Td
[(10.)-875.1 (T)69.9 (am SW)91.7 (, )17.7 (W)79.9 (orcel M, )17.7 (W)59.9 (yllie M. )36.8 (Y)99.8 (ohimbine: a clinical review)64.8 (.)]TJ
0.00729 Tw 2.175 -1.25 Td
[(Pharmacol Ther )-17.7 (2001;91:215-43.)]TJ
0.02499 Tw -2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Stur)17.7 (gill MG, Grasing KW)91.7 (, Rosen RC, et al. )36.8 (Y)99.8 (ohimbine elimination)]TJ
2.1381 -1.25 Td
(in normal volunteers is characterized by both one- and)Tj
T*
[(two-compartment behavior)54.8 (. J Cardiovasc Pharmacol )]TJ
0 Tc 0 Tw T*
(1997;29:697-703.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(12.)-875.1 (Le Corre P)110.7 (,)-0.1 ( Dollo G, Chevanne F)79.7 (, Le )17.7 (V)110.8 (e)0.3 (r)17.7 (ge R. Biopharmaceutics)]TJ
2.175 -1.25 Td
(and metabolism of yohimbine in humans. Eur J Pharm Sci)Tj
0 Tc 0 Tw T*
(1999;9:79-84.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(13.)-875.1 (Flavahan NA, Flavahan S, Liu Q, et al. Increased alpha-2 )]TJ
2.175 -1.25 Td
[(adrener)17.7 (gic constriction of isolated arterioles in dif)17.7 (fuse scleroderma.)]TJ
T*
(Arthritis Rheum 2000;43:1886-90.)Tj
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_2 1 Tf
8 0 0 8 54.5 35.9844 Tm
[(Johnson, et al: RP)-257.3 (Y)91.8 (ohimbine therapy)]TJ
0 Tc 0 Tw 60.9375 -0.0313 Td
(2505)Tj
ET
0 0 0 0 k
/GS0 gs
109.22 59.09 396.48 -10.84 re
f*
0.5 w
109.22 59.09 396.48 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_4 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
11 0 obj
<>stream
8;Z\5>7uQB#i,;aOR%")GZfkHN;_t)[9=Sj=WS_SNQ+`p[hol;DWN-h_La:YG9!:?
q^po^lR`@[%jYdKaA7*\GEo\`f:tn.3XtC9RUI&oN5]Sk$pf^F^)ge8cjQVLY!&\M
OKldGOED=H=kjI,:eHL'D_#*j*GmNgG&ae-V,:tJ`CW>h(fCO$<.W?j.QGmHLRT#Y
l'A5O/PEY0EWhr2>f\&\2DLn4PXEg]>r,)f:*+Nt,4)J.X5O?0d=c8&epI^)Wa*M#
@+d9!%W4K=-GD&?+Xo()7,Ne[gOlMA0u%$OITX;V?^UJc*>,Vb#&.J]:5+\74X+2.
67->"*FtFq%:#9S6.9L()N@4]d:b?TNQ/^7qfmd)_>%,S/<5a#pZ$0?q?+A7!'msLU&~>
endstream
endobj
15 0 obj
[/Indexed/DeviceRGB 255 14 0 R]
endobj
14 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
38 0 obj
<>
endobj
42 0 obj
<>
endobj
41 0 obj
<>
endobj
48 0 obj
<>
endobj
78 0 obj
<>
endobj
90 0 obj
<>
endobj
47 0 obj
<>
endobj
72 0 obj
<>stream
HLSkPW%d/4*k|ltwUjU<[mPSCЂ@XTD.]Z[QLѾ!v>8ӳɌX8Ι;g=w]
hH:?-ebK1)n fc1!
Q*BpKҏZCЮJKa;C'ƨFc,{~dywU8>{r0>or+bG9!ڲR]2s&b*f+8,Uh$S9$bf/(7I&[$ZwK$Y̎'o]>>=4Ezj(jJ5UC
V%B)B(CR搛TMW-ҩJ"zƟ"뗹?8t(#JμRKQŻ8x`LI{ŕy n>BsjA#keļ댝=&!+< pдv^ua52`.E#qP
n}uA,+HrD?6Hf
j#q0e%t.x
n+J h1⦩0tƦF-GpᡊGiw*pVWFI$hU&[30Y!@9>-po
SC qSMf-u
$gqzPLR8(%ј]ĔN/CaQ.@⁴UnFd?#Ӡ5ݜ$_2Hי'`9Uµ(Y2lE2Tvw֩,T0g4lUHoY{8&w%fGkEH}ͼ?nR4(c8#zL2X`6B[(fb4A&uMq61)<U-R|~srN`缧hߵ&Ĺ;xa{%yɢu7ݕK7PqQ328d
çWߪ}]ۧމoJAḴ0Wե,$RJM$ukam ״`bt*ho-7(NŮ<,//)6+NϪxګ3u1gEv!h 6jekj:- te._eǞv]:6W+0\}Stg/_pC5ou~={?
Vm!mQC{gx>g=:0D S
endstream
endobj
40 0 obj
<>
endobj
73 0 obj
<>stream
HTyPwFAp%jLJ5끈Ap
%dQ9@9`Dn/xƓU
F
)C5Ljڕ#U~8fk8/`@Tx}bjM#8i!a||4ߖ'HK/07ٰ66BSH.KvRK^=1]M?;6}\x}L '
ߚ0ᐣ̱ϩyw2i<K^7g V
\5,__s0{O_?Sә-5E&kiML(MV$)TPv.c?HbdUcبd*l nxrn~ sx
,'4)M7֘pRrRkmwݖ\r^Qz#r9L*PkگiAi#oDp1:#
)*ၪ=y4bGȭ)B5ԛx-}e"AC@?>%8wpg4fN)D;(E}_Svtխ,NnA6\}i[cۆK-7leLUO}_A >&1=m}Tjh2"I9C: n/"=qIj|dY(U~4<3P,h+><'c37*e2JfD4ԨŲPJ'P`=9@МGnr/n\İʨwP
L~iM VXd"m63;,,#5+X-K4dH qSAihr&3dik%O uA[hT8PO¨"D+6N90}" /ULlӖD=`\y -Кo^˹@*g?lj0+5BDޠ8aaa)Pd~$>X A >0m4oX2>v\嘅AoՄsu8Ō
##:~&^j=%$(3InKӶYs&ޮĽDzD3!rrg!7Uot@uX^@ ó5;+$UD#u\Z
i(TPKHU%[A XVTS_g9^U?fJyQ[
ڔ&oK~jcY-kn;OMaO&7Ctsxey"dfnD~wQ0%՝nj{PQ*NҦdnXhԀZ)`wi s:ZpKp<̂͢}Lyܯ/6JѢEi3zSuY}N]mr*H3+[u"6DTQ!ɲB4!NMky䈔r*+끕dN*䒇ȍ @sp>^hBf5|hSh'vg%n+~41=<3_}b*i#9ITDtzN^<\6F"4yafP,.ЯCC-8 %3W@BrT46},!PNB+|&or6e۹ƶ[Uu_Xwc˰;1R%ψQܢ2Ix5ugahLrml%NW֪K]jUt+Q"% yI BB&Gx""UL[J:kwSu]
nis|Tq$BI"^ëYh;D3zi`CL~DN+,X
/PǾ2}"`3`F2P~CBuȧ2@lx7(JV=kc#%MK9,@Yl
#Y*ڠwш?T
R˳}%o)`(`AJ%*3f*ދ4Vu`QKG'wjU9;6Q8UA$ 2!_KByvleδt ^3jC4{
~HذvΫSs%ߟzẁ9 $`aż!qiHG6[9cm9ݰ*zj~G'VIEXe.;?9+`mҘ+U}YhL+F{
~F`>K4 y$)֧M8A!8MWcA}]@܃7=35 \S pVXd~+
'MQH}ƜJ⪶+"i\ޒ u1QS]7TLY)V